Niamh O’Luanaigh, Chief Operating Officer, Biosensia. Photo: Nick Bradshaw, Fotonic.
Biosensia has been funded by Atlantic Bridge, Seroba Life Sciences, ACT Venture Capital, Street Capital and others previously
Kypha, a US medical diagnostics company, developing specialised biomarker testing solutions for precision monitoring of immune status and inflammation, has acquired Biosensia, an Irish diagnostics platform and contract development company, to strengthen Kypha’s product portfolio.
Biosensia, established in 2009, is headquartered at NovaUCD, the Centre for New Ventures and Entrepreneurs at University College Dublin, and will continue to operate as a wholly-owned subsidiary of Kypha.
Proprietary diagnostic systems capable of producing laboratory quality results
Biosensia’s RapiPlex is a proprietary diagnostic system designed to support CLIA-waived protocols and is capable of producing laboratory quality quantitative and qualitative results with a disposable cartridge for up to 24 biomarkers in a multiplex format.
“The proprietary technologies and core competencies of each company are perfectly synergistic. Blending them enhances and accelerates the delivery of our products to health care practitioners, researchers and pharmaceutical companies seeking to more precisely assess and monitor immune status dynamics. The addition of Biosensia’s EU-based ISO-certified facilities and deeply experienced core team allows us to bring product development, quality control and test manufacturing in house and continue to provide contract assay development and manufacturing services to Biosensia clients around the world,” according to Dr Chad Stiening, Chief Executive Officer, Kypha.
Niamh O’Luanaigh, Chief Operating Officer, Biosensia, said, “We are very excited about bringing our advanced platform together with Kypha’s specialised biomarker testing and achieving the clinical impact that we designed RapiPlex to fulfil.”